GE Healthcare, a unit of General Electric Co., has acquired Wave Biotech LLC, a supplier of disposable manufacturing technologies for the biopharmaceutical industry. The acquisition of Wave Biotech LLC, including its subsidiary Wave Europe Pvt. Ltd., expands GE Healthcare’s products and services for the manufacture of biopharmaceuticals such as antibodies and vaccines. Financial terms were not disclosed.

Wave Biotech develops and manufactures bioreactors designed to replace traditional and more expensive stainless steel tanks and piping. Wave Biotech’s single use bioreactors are also increasingly being used to enable the manufacture of patient-specific cell and gene therapy products.

Ann O’Hara, general manager of GE Healthcare’s BioProcess business, said, “Wave Biotech is an excellent company with a strong track record of innovation and a product range that is highly complementary with our existing BioProcess business. The combination of GE Healthcare and Wave Biotech will allow us to expand into new applications and to create a broad offering of added value tools and services for biopharmaceutical manufacture.”

“We are very excited to be part of GE Healthcare, who already offer a broad range of technologies and services to the biopharmaceutical manufacturing industry,” said Dr. Vijay Singh, president and founder of Wave Biotech. “Our customers will benefit greatly from the global presence and the R&D resources that GE Healthcare brings to the table. The integration of single-use cell culture with GE Healthcare’s existing filtration and downstream operations will provide a host of new disposable solutions to this growing industry.”